ES2413631T3 - Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades - Google Patents

Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades Download PDF

Info

Publication number
ES2413631T3
ES2413631T3 ES10188586T ES10188586T ES2413631T3 ES 2413631 T3 ES2413631 T3 ES 2413631T3 ES 10188586 T ES10188586 T ES 10188586T ES 10188586 T ES10188586 T ES 10188586T ES 2413631 T3 ES2413631 T3 ES 2413631T3
Authority
ES
Spain
Prior art keywords
soluble
disease
prevention
treatment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10188586T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Steinkasserer
Matthias Lechmann
Elisabeth Zinser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merix Bioscience Inc
Original Assignee
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merix Bioscience Inc filed Critical Merix Bioscience Inc
Application granted granted Critical
Publication of ES2413631T3 publication Critical patent/ES2413631T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
ES10188586T 2002-11-19 2003-11-19 Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades Expired - Lifetime ES2413631T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025851 2002-11-19
EP02025851A EP1422241A1 (en) 2002-11-19 2002-11-19 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases

Publications (1)

Publication Number Publication Date
ES2413631T3 true ES2413631T3 (es) 2013-07-17

Family

ID=32187165

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10188586T Expired - Lifetime ES2413631T3 (es) 2002-11-19 2003-11-19 Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades
ES03767573.3T Expired - Lifetime ES2534308T3 (es) 2002-11-19 2003-11-19 Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03767573.3T Expired - Lifetime ES2534308T3 (es) 2002-11-19 2003-11-19 Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades

Country Status (9)

Country Link
US (3) US7893200B2 (https=)
EP (5) EP1422241A1 (https=)
JP (3) JP4740595B2 (https=)
AU (1) AU2003292045A1 (https=)
CA (2) CA2507373C (https=)
DK (1) DK1562985T3 (https=)
ES (2) ES2413631T3 (https=)
SI (1) SI1562985T1 (https=)
WO (1) WO2004046182A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
JP5570808B2 (ja) * 2006-08-18 2014-08-13 アルゴス・セラピューティクス・インコーポレーテッド 併用療法におけるｃｄ８３の使用
EP2254998B1 (en) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
MX2010012576A (es) * 2008-05-23 2011-04-05 Argos Therapeutics Inc Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.
US20120322085A1 (en) * 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
CN104610452B (zh) * 2015-01-27 2018-11-20 中国科学技术大学先进技术研究院 抗人cd83单克隆抗体及其制备、鉴定和应用
JP7228824B2 (ja) 2015-06-30 2023-02-27 国立大学法人大阪大学 抗プレキシンａ１アゴニスト抗体
EP3534960A4 (en) 2016-11-07 2020-05-13 Coimmune, Inc. SPECIFIC ANTIBODIES MODULATING AND USING THE TLR-4 SIGNALING
US11252960B2 (en) 2017-01-31 2022-02-22 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
EP3895723A1 (en) 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) * 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU2273397A (en) * 1996-02-15 1997-09-02 Immunex Corporation Methods and compositions for modulating an immune response
WO1999010492A1 (en) 1997-08-26 1999-03-04 Zymogenetics, Inc. Adipocyte-specific protein homologs
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB2370273A (en) 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
AU2002240734A1 (en) * 2001-10-18 2003-04-28 Zlatko Ademovic Repetitive motifs from salivary proline rich proteins, mucin and collagen
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2003045318A2 (en) 2001-11-21 2003-06-05 Celltech R & D, Inc. Manipulation of cytokine levels using cd83 gene products
US6652537B2 (en) 2001-12-12 2003-11-25 C. R. Bard, Inc. Articulating stone basket
US20030219436A1 (en) 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
JP2006503110A (ja) 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
MX2010012576A (es) 2008-05-23 2011-04-05 Argos Therapeutics Inc Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.

Also Published As

Publication number Publication date
CA2847795A1 (en) 2004-06-03
EP1562985B1 (en) 2015-01-07
US7893200B2 (en) 2011-02-22
US20070167607A1 (en) 2007-07-19
EP1422241A1 (en) 2004-05-26
EP3031824A1 (en) 2016-06-15
CA2847795C (en) 2018-05-01
JP2011144177A (ja) 2011-07-28
JP5878584B2 (ja) 2016-03-08
EP2345670B1 (en) 2013-03-20
WO2004046182A3 (en) 2004-10-14
HK1194400A1 (en) 2014-10-17
SI1562985T1 (sl) 2015-05-29
AU2003292045A8 (en) 2004-06-15
JP4740595B2 (ja) 2011-08-03
CA2507373A1 (en) 2004-06-03
JP2014195455A (ja) 2014-10-16
JP2006523432A (ja) 2006-10-19
US8759505B2 (en) 2014-06-24
AU2003292045A1 (en) 2004-06-15
US20150065684A1 (en) 2015-03-05
JP5557765B2 (ja) 2014-07-23
WO2004046182A2 (en) 2004-06-03
US20120015890A1 (en) 2012-01-19
US9732140B2 (en) 2017-08-15
EP2345670A1 (en) 2011-07-20
EP2692733A1 (en) 2014-02-05
CA2507373C (en) 2014-06-10
EP2692733B1 (en) 2015-11-18
EP1562985A2 (en) 2005-08-17
HK1079220A1 (en) 2006-03-31
ES2534308T3 (es) 2015-04-21
DK1562985T3 (da) 2015-04-13

Similar Documents

Publication Publication Date Title
ES3036912T3 (en) Neoantigens and methods of their use
US8124099B2 (en) Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
JP5878584B2 (ja) 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
ES2440974T3 (es) Constructos poliepitópicos del VPH y uso de los mismos
US9102726B2 (en) Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN113577256A (zh) 药物组合物的应用
AU2020351062B2 (en) IL-10/Fc fusion proteins useful as enhancers of immunotherapies
ES2433915T3 (es) Vacunas de ADN que codifican proteínas de choque térmico
JP2004516024A (ja) Ｃｄ８３発現に影響を及ぼす化合物、前記化合物を含む薬剤組成物及び前記化合物を同定する方法
US8679780B2 (en) Method of reducing immunological tolerance to malignancy
HK1194400B (en) Nucleic acids encoding soluble forms of cd83
HK1079220B (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases